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Víctor Martínez-Rosas a,d, Laura Morales-Luna a,b, Josué Martínez-Miranda e, Edgar Sierra- 
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A B S T R A C T   
Background: The pentose phosphate pathway (PPP) has received significant attention because of the role of 
NADPH and R-5-P in the maintenance of cancer cells, which are necessary for the synthesis of fatty acids and 
contribute to uncontrollable proliferation. The HsG6PD enzyme is the rate-limiting step in the oxidative branch 
of the PPP, leading to an increase in the expression levels in tumor cells; therefore, the protein has been proposed 
as a target for the development of new molecules for use in cancer. 
Methods: Through in vitro studies, we assayed the effects of 55 chemical compounds against recombinant 
HsG6PD. Here, we present the kinetic characterization of four new HsG6PD inhibitors as well as their functional 
and structural effects on the protein. Furthermore, molecular docking was performed to determine the inter-
action of the best hits with HsG6PD. 
Results: Four compounds, JMM-2, CCM-4, CNZ-3, and CNZ-7, were capable of reducing HsG6PD activity and 
showed noncompetitive and uncompetitive inhibition. Moreover, experiments using circular dichroism and 
fluorescence spectroscopy showed that the molecules affect the structure (secondary and tertiary) of the protein 
as well as its thermal stability. Computational docking analysis revealed that the interaction of the compounds 
with the protein does not occur at the active site. 
Conclusions: We identified two new compounds (CNZ-3 and JMM-2) capable of inhibiting HsG6PD that, 
compared to other previously known HsG6PD inhibitors, showed different mechanisms of inhibition. 
General significance: Screening of new inhibitors for HsG6PD with a future pharmacological approach for the 
study and treatment of cancer.  
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1. Introduction 
The pentose phosphate pathway (PPP) is the metabolic pathway 
known as the hexose monophosphate shunt and consumes glucose-6- 
phosphate as a primary substrate. The PPP is a metabolic pathway 
from which a cell that is proliferating is supplied with both the nucle-
otide precursors needed for proliferation and reduced nicotinamide 
adenine dinucleotide phosphate (NADPH), a fundamental molecule for 
the synthesis of fatty acids, which are essential in the synthesis of cell 
membranes [1]. Additionally, NADPH is used for intracellular ROS 
detoxification because the electrons of NADPH are used by the gluta-
thione reductase enzyme for the generation of reduced glutathione 
(GSH), providing the first line of defense against ROS and preventing the 
accumulation of these toxic species in the cell [2–5]. 
The G6PD enzyme catalyzes the first and rate-limiting step of the 
oxidative phase in the pentose phosphate pathway (PPP), and together 
with the 6-phosphogluconate dehydrogenase (6PGD) enzyme, it pro-
duces the reduced form of nicotinamide adenine dinucleotide phosphate 
(NADPH) [6]. Recently, it has been observed that in diseases such as 
diabetes, heart failure, pulmonary insufficiency, and cancer, human 
G6PD (HsG6PD) activity is deregulated [7–11]. Furthermore, several 
researchers have paid considerable attention to the PPP, especially in 
the role of HsG6PD in cancer. In this sense, various studies have reported 
that there is an increase in the levels of expression in the mRNA of the 
G6PD gene in several types of neoplasms, such as breast [12], colon 
cancer [13], and gliomas [14]. The latter is due to the crucial role of 
NADPH and ribose-5-phosphate in maintaining cancer cells, which are 
required for the synthesis of fatty acids, contributing to uncontrollable 
proliferation and increased cell survival under stress conditions. More-
over, it has been shown that the PPP plays a role in cisplatin resistance. 
Cisplatin is the first-line treatment for different types of solid tumors, 
and the overexpression of this gene combined with high activity of G6PD 
increases drug resistance [15]. In addition, the increase in glucose in the 
PPP to support anabolic demands in cancer increases oxidative stress, 
endoplasmic reticulum stress, and apoptosis [16]. 
HsG6PD is the rate-limiting step in the oxidative branch of the PPP 
[1], and this enzyme is highly regulated in normal cells. Transcriptional 
regulation of the G6PD gene is carried out by the interaction of mech-
anistic target of rapamycin complex 1 (mTORC1) with the transcrip-
tional factors sterol regulatory element-binding proteins (SREBP) and 
Tap73 in the G6PD gene [17,18] and by posttranscriptional signaling 
cascades such as the 1-phosphatidylinositol 3-kinase-protein kinase B 
pathway (PI3K-AKT) through p53 [19], phosphatidylinositol-3,4,5- 
triphosphate 3-phosphatase (PTEN) [20] and ataxia-telangiectasia 
mutated kinase (ATM) through HBSP1 [21] as well as alterations in 
the NADPH/NADP+ ratio [22]. However, in tumor cells, the regulation 
of HsG6PD is altered by genetic and metabolic modifications. Compared 
to normal cells, higher expression of HsG6PD and greater activity have 
been reported [12]; the inhibition of IRE1 (inositol requiring enzyme 1) 
in U87 glioblastoma cells modifies the hypoxia response and increases 
the gene expression of some enzymes of the PPP, including G6PD [23]. It 
has been observed that this overexpression of HsG6PD in cancer cells 
confers proliferative advantages and greater protection against oxida-
tive damage [6,24], leading to increased resistance by tumor cells to 
chemotherapy treatments such as the use of cisplatin [12]. Based on the 
above, different therapeutic alternatives have been studied to try to 
affect the metabolism of tumor cells. One option has been to inhibit the 
activity of HsG6PD to attempt to reduce the uncontrollable proliferation 
presented by cancer cells as well as to make them vulnerable to tradi-
tional therapies. Previously, chemical compounds that reduce G6PD 
activity, such as dehydroepiandrosterone (DHEA) and 6-aminonicotina-
mide (6AN), have been analyzed; however, these inhibitors have not 
been used for therapy because they have severe side effects, such as 
nerve damage and vitamin B deficiency [25]. On the other hand, Preuss 
et al. [26] proposed novel G6PD inhibitors for recombinant human 
G6PD and found that only one inhibitor had a negative effect on cellular 
viability in the MCF10 model of mammary carcinoma. Naringenin (a 
flavanone) has also been proposed as an inhibitor of glial cell tumori-
genesis in glioma C6 cells implanted in rats, modifying metabolic 
markers, including G6PD enzyme activity [27]; the antioxidant and 
antiproliferative effects of curcumin and polyunsaturated fatty acids 
have also been shown in rat glioma C6 cells [28,29]. Currently, G6PD 
gene expression is proposed as a biomarker for the risk and prognosis of- 
and chemosensitivity to- glioma [30]. 
Based on the necessity of finding new inhibitors against HsG6PD, in 
this study, we investigated the effects of an in-house library comprising 
55 synthetic compounds on the activity of the human recombinant G6PD 
enzyme. Furthermore, we found and described HsG6PD inhibition by 
four of these compounds, where JMM-2, CCM-4, CNZ-3, and CNZ-7 
compounds were also capable of reducing HsG6PD activity and showed 
noncompetitive and uncompetitive inhibition. It is interesting to note 
that this is the first time that the effect of these compounds on the sec-
ondary and tertiary structure of the protein has been observed as well as 
thermal stability (global stability of the protein) in the HsG6PD protein. 
Finally, by molecular blind docking, we determined the possible struc-
tural inhibitor binding site in this enzyme. 
2. Materials and methods 
2.1. Expression and purification of recombinant HsG6PD protein 
All the assays in the present study were performed using recombi-
nant human glucose-6-phosphate dehydrogenase (HsG6PD). The protein 
was overexpressed and purified according to the reported method by 
Gómez-Manzo et al. [3]. The protein purity was verified with 12% so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
and then the gel was stained with colloidal Coomassie (R-250) (Sigma- 
Aldrich, San Luis, Misuri, USA). 
2.2. Compounds library and high-screening assay 
The high screening assay was performed using 55 compounds 
belonging to an in-house library synthesized in the Medicinal Chemistry 
Laboratory from Universidad Autónoma from Estado de Morelos, Fac-
ulty of Pharmacy (Supplementary Materials Table S1). In-house libraries 
are advantageous in discovering novel bioactive small molecules. All 
assays were performed with 0.2 mg/mL HsG6PD protein, and the 
compounds were tested to a final concentration of 400 μM. Dimethyl 
sulfoxide (DMSO) was used to solubilize the compounds, and we verified 
that the final concentration of DMSO did not exceed 5% and did not 
affect the catalytic activity of HsG6PD [26]. The enzyme was incubated 
with each of the compounds for two hours at 37 ◦C, and then the residual 
activity of HsG6PD was measured with a standard reaction mixture (100 
mM Tris-HCl buffer, pH 8.0, 3 mM MgCl2, 200 μM G6P (~5-fold of the 
Km value = 38.4 μM), and 35 μM NADP+ (~5-fold of the Km value = 35 
μM)), following NADPH production at 340 nm. The enzyme activity 
without compounds was adjusted to 100%. Compounds that inhibited 
HsG6PD activity by more than 50% were considered hit candidates to 
perform the following experiments. Three experiments were performed 
for this assay. 
2.3. Orthogonal assays 
Selected hit compounds (four compounds) were used to determine 
the IC50 values (the concentration of the compound at which the protein 
loses 50% of its activity). The orthogonal assays were performed with 
0.2 mg/mL HsG6PD protein previously incubated for 2 h at 37 ◦C with 
increasing concentrations ranging from 0 to 800 μM of the four com-
pounds selected in the high-screening experiment. Then, the residual 
HsG6PD activity was measured, and the initial velocities obtained were 
plotted versus compound concentration. The enzyme activity without 
compounds was adjusted to 100%. The IC50 values were calculated using 
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the Origin 8.0® program. Three experiments were performed for this 
assay. 
2.4. Second-order inactivation constant (k2) of HsG6PD exposed to 
selected hit compounds 
The second-order inactivation constant k2 (M− 1 s− 1) was used to 
determine the inactivation rate of each compound and to represent the 
rate of formation of the enzyme-inhibitor complex. First, the pseudo-first 
order inactivation rate constants (k1) were obtained from 0 to 1 mM for 
the four compounds. The HsG6PD protein (0.2 mg/mL) was incubated 
with four fixed concentrations of each of the compounds, and at the 
indicated times, aliquots were withdrawn to determine residual activity. 
The residual activity data were fitted using the following mono-
exponential decay equation AR = A0 e− kt to obtain the pseudo-first order 
rate constant (k1) values at each fixed concentration of compounds. 
Then, to obtain the second-order rate constants of inactivation, the k1 
values of each compound were plotted against the employed concen-
trations of each compound, and the second-order rate constant value of 
inactivation k2 (M− 1 s− 1) was obtained from the slope of these plots as 
previously described [31,32]. 
2.5. Determination of inhibition type 
To determine the inhibition mechanism of the four selected hit 
compounds, we evaluated changes in the Vmax and Km parameters for the 
HsG6PD enzyme in the presence of four fixed concentrations of each of 
the compounds. The main kinetic parameters (Km and Vmax) were 
determined by measuring the initial rates at different substrate con-
centrations. Initial velocities for the G6P substrate were obtained by 
varying the G6P substrate (0 to 250 μM), while NADP+ was fixed at a 
saturating concentration (~5-fold of the Km value = 35 μM). For initial 
velocities of the NADP+ substrate, this varied from 0 to 250 μM, and the 
G6P substrate was fixed at a saturating concentration (~5-fold of the Km 
value = 38.4 μM). The parameters Km and Vmax for the four compounds 
were obtained by fitting the data to the Michaelis-Menten equation by 
nonlinear regression calculations using the Origin 8.0® program [3]. All 
the initial rate measurements were carried out in triplicate. The initial 
activities were fitted to the Michaelis–Menten equation by nonlinear 
regression calculations to obtain the parameters Vmax and Km. To 
determine the inhibition mechanism of the four compounds in the 
HsG6PD enzyme, the experimental data were analyzed using the double 
reciprocal plot method. The inactivation constant (Ki) was obtained by 
plotting the value of the slope obtained at each of the fixed concentra-
tions of each compound in the double reciprocal graph against the 
concentration of the compound. Then, the data were adjusted to a linear 
regression model, where the interception with axis y was the determined 
Ki value (μM). 
2.6. Structural studies of HsG6PD enzyme with the compounds 
2.6.1. Circular dichroism (CD) and thermal stability assays 
To determine whether the loss of HsG6PD activity caused by the 
inhibitors was due to alterations in the secondary structure of the pro-
tein, we performed a circular dichroism (CD) assay in the presence of 
each inhibitor. The secondary structure of the HsG6PD protein was 
analyzed by CD in a spectropolarimeter (Jasco J-810®, Inc., MD, USA). 
The protein was adjusted to 0.2 mg/mL with buffer P (50 mM phosphate 
pH 7.35), incubated for 2 h at 37 ◦C in the absence and presence of the 
compounds (IC50 of each compound) and loaded in a rectangular quartz 
cuvette with a 1 cm optical path. Spectra were recorded at 25 ◦C in ul-
traviolet circular dichroism (UV-CD) ranging from 200 to 260 nm by 
monitoring changes in the emission of the molar ellipticity of the spectra 
at 222 and 208 for the α–helices and β–sheets, respectively. Spectra of 
the blanks (buffer P solution containing each of the compounds) were 
subtracted from all the obtained spectra that contained the protein [33]. 
The curves were plotted using the Origin 8.0® program. 
Furthermore, the thermal denaturation of HsG6PD in the presence of 
the four inhibitors was performed by monitoring the unfolded fraction at 
222 nm as a function of temperature, ranging from 35 to 70 ◦C and 
increasing at a rate of 1 ◦C/2.5 min. The assay was performed in a 
spectropolarimeter Jasco J-8190, as previously reported [5]. The pro-
tein was adjusted to 0.2 mg/mL with buffer P and incubated for 2 h at 37 
◦C in the absence and presence of four compounds (IC50 of each com-
pound). The data were adjusted with the Boltzmann equation using the 
Origin 8.0® program to obtain the Tm. value (the temperature at which 
50% of the protein is folded and 50% is unfolded, expressed as the 
melting temperature). Both experiments were performed in triplicate. 
2.6.2. Intrinsic and extrinsic fluorescence assays 
To evaluate the structural changes in HsG6PD with the four com-
pounds, we performed intrinsic and extrinsic fluorescence assays. For 
the intrinsic fluorescence assay, the HsG6PD protein was adjusted to 0.1 
mg/mL in buffer P and incubated for 2 h at 37 ◦C in the absence or 
presence of each of the compounds at the IC50 concentration. The 
intrinsic fluorescence spectra were recorded at 310–500 nm in a Perkin- 
Elmer LS-55 fluorescence spectrometer (Perkin Elmer®, Wellesley, MA, 
USA) using an excitation wavelength of 295 nm and slits of excitation 
and emission of 10 and 10 nm, respectively. The final spectrum was the 
average of five scans; later, each spectrum was subtracted from the 
spectra of the blank (buffer P solution containing each of the compounds 
without protein) [34]. 
Furthermore, we determined the extrinsic fluorescence of the 
HsG6PD enzyme in the presence of the four compounds by an 8-anilino-
naphthalene-1-sulfonic acid (ANS) assay to monitor changes in the hy-
drophobic regions of the protein. The protein was incubated under the 
same conditions as the intrinsic fluorescence assay. Then, we recorded 
the fluorescence spectra from 400 to 600 nm in the presence of 25 mM 
ANS dissolved in methanol. The assay was carried out at 25 ◦C with a 
scanning rate of 200 nm/min. The samples were excited to 395 nm using 
slits of excitation and emission of 10 nm. The final spectrum was the 
average of five scans. Later, each spectrum was subtracted from the 
spectra of the blank (buffer P solution containing each of the compounds 
plus ANS). 
2.7. Blind molecular docking 
The crystal structure of HsG6PD [35] was downloaded from the 
Protein Data Bank (PDB ID: 2BHL, http://www.rcsb.org/pdb). The 3D 
structures of the compounds were generated in Chem-Draw Professional 
16.0; they were assembled with Molecular Operating Environment 
(MOE) software. This crystal structure was complexed with two mole-
cules of NADP+ (structural and catalytic binding sites), which were 
maintained for the docking analysis, and the rest of the pockets were 
emptied, removing all the water molecules and heteroatoms from the 
PDB file; this process was performed using the open-source program 
PyMOL (The PyMOL Molecular Graphics System, Version 2.0 
Schrödinger, LLC, New York, NY, USA). After this process, the protein 
was analyzed with the program Molecular Operating Environment 
(MOE) to verify that there were no incomplete domains or fragments, 
and system energy minimization was also performed. 
2.7.1. Preparation of the ligand PDB files 
The 3D structures of the docked compounds were obtained from 
MOE, reducing the system energy, and a protonated state was consid-
ered if the compounds had an ionic group. The files were saved as *.PDB 
files. 
2.7.2. Preparation of the.Pdbqt files 
The *.pdbqt files of the receptor and the ligands were obtained using 
the Autodock Vina input in PyMOL, and because this was a “blind 
docking”, there was no need to define the binding pocket of the receptor. 
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2.7.3. Defining the grid box 
The grid box parameters were defined using the AutoDock Vina input 
in PyMOL. In this case, no specific area was defined, so the entire protein 
was enclosed in the grid box, adding 5 Å in each axis to ensure that the 
entire protein was enclosed in the grid box. The total dimensions of the 
grid box were as follows: X: 72 Å, Y: 67 Å, and Z: 96 Å. 
2.7.4. Docking 
The docking was performed in Linux, performing 100 independent 
experiments and obtaining 10 results in each experiment, with a total of 
1000 results per ligand. The affinity energies and the tridimensional 
configuration of each ligand were analyzed to select the best 100 results 
(both energy and tridimensional configurations were selected and 
categorized as reliable and repeatable results). For the affinity energies 
and tridimensional configuration, the mean and the standard deviation 
were calculated. 
The docking protocols were validated by the redocking of NADP+
located in the HsG6PD catalytic binding site of 2BHL. A root-mean- 
square deviation (RMSD) value less than 2.0 Å between the cocrystal 
coenzyme and the docked NADP+ was considered the parameter to 
determine that the docking calculations reproduced the conformation 
and orientation in the X-ray crystal of HsG6PD. Finally, the generated 
docking results were directly loaded into PyMOL (The PyMOL Molecular 
Graphics System, Version 2.0 Schrödinger, LLC, New York, NY, USA). 
3. Results 
3.1. Biochemical assays 
3.1.1. Selection of HsG6PD inhibitors 
High-throughput screening (HTS) assays were performed to identify 
molecules that modified the activity of the HsG6PD protein. Previously, 
Preuss et al. [26] found five compounds that are capable of inhibiting 
the activity of HsG6PD. Based on this information, we analyzed a library 
of 55 compounds with similar structures to those previously reported 
[26] at a final concentration of 400 μM, which were chemically similar 
to those reported by Preuss et al. [26], and we found that four chemical 
compounds, named JMM-2, CCM-4 CNZ-3, and CNZ-7, were also 
capable of reducing the activity of the human G6PD enzyme by more 
than 40% (Table 1). 
The compounds JMM-2 and CCM-4 are structurally similar, as both 
have a biphenyl ring in their structure; however, JMM-2 comes from 3- 
phenylpropanoic acid and CCM-4 from phenylacetic acid. We observed 
that of these two compounds, JMM-2 showed the highest percentage of 
inhibition on recombinant HsG6PD with 89.5% inhibition (Table 1), 
while compound CCM-4 derived from phenylacetic acid showed 47.3% 
inhibition of HsG6PD activity. These results could indicate that it is 
necessary for the molecule to have a carboxylic acid chain of at least 
three carbon atoms to achieve a percentage of enzyme inhibition greater 
than 80%; this feature is present in compound JMM-2. 
On the other hand, compounds CNZ-3 and CNZ-7 are analogs of 
nitazoxanide, a well-known antiparasitic compound. Structurally, they 
have a 5-nitro-2-aminothiazole ring connected by a urea bridge with a 
benzamide ring. However, compound CNZ-3 has a p-chloro substituent 
in the benzamide ring and showed 92.6% inhibition of HsG6PD activity, 
while compound CNZ-7 has an n-butyl ether substituent in the same 
position—this radical has more volume and is less electronegative than 
the p-chloro substituent-and showed inhibition of 68.0% of HsG6PD 
activity (Table 1). 
These results indicate that the inhibition of the HsG6PD enzyme 
depends on the structural characteristics and physicochemical proper-
ties of each compound. Furthermore, we observed that the inhibition 
was lower in the compounds that have more volume in their functional 
groups, as in the case of CNZ-7. The four chemical compounds selected 
in this first assay were used to perform biochemical and physicochem-
ical assays (Table 1). 
3.1.2. Orthogonal assay 
Given that four compounds (JMM-2, CCM-4, CNZ-3, and CNZ-7) 
showed a high percentage of inhibition of HsG6PD, we analyzed the 
concentration response to determine the IC50. The IC50 values deter-
mined for the chemical compounds JMM-2, CCM-4, CNZ-3, and CNZ-7 
were 307 μM, 412 μM, 121 μM, and 274 μM, respectively. As seen in 
Fig. 1, compared to the other three compounds, the HsG6PD enzyme lost 
activity faster with the compound CNZ-3, showing a greater negative 
effect on the catalytic activity of HsG6PD at low concentrations. The 
differences in the IC50 values between these chemical compounds were 
probably due to the structural differences that each compound presents, 
Table 1 
Synthetic compounds from an in-house library that showed an inhibition percentage greater than 40% on HuG6PD activity at a final concentration of 400 μM.  




CNZ-7 68.0  
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as was observed in the high-throughput screening (HTS) assay. It is 
interesting to note that the four compounds tested here inhibited the 
activity of HsG6PD to different extents, and the inhibitory effect 
revealed a concentration-dependent inhibition (Fig. 1). 
3.1.3. Second-order inactivation constants (k2) of HsG6PD in the presence 
of four compounds 
To determine the ratio formation of the complex enzyme inhibitors 
of each of the chemical compounds with the HsG6PD enzyme, we first 
calculated the pseudo-first order inactivation constants (k1) after the 
enzyme was incubated with different fixed concentrations of each 
compound, and the initial velocities were measured at different incu-
bation times. The synthetic compounds, JMM-2 and CCM-4, showed 
single-exponential decays of time-course inactivation and had a negative 
effect on the catalytic activity of the HsG6PD enzyme (Fig. 2A, C). From 
this plot, we calculated the k1 values for each compound and plotted 
them against the concentrations (Fig. 2B, D, respectively), and linear 
behavior was obtained. The calculated k2 value for JMM-2 was 0.50 
M− 1 s− 1, while for CCM-4, the calculated k2 value was 0.63 M− 1 s− 1. 
On the other hand, the CNZ-3 and CNZ-7 compounds also showed 
single-exponential decays of time-course inactivation (from 0 to 120 
min) (Fig. 2E, G). As seen in Fig. 2, as the concentration of the chemical 
compounds CNZ-3 and CNZ-7 increased, the HsG6PD enzyme lost cat-
alytic activity in a shorter incubation time; as expected, in the HsG6PD 
enzyme that was not incubated with the chemical compounds, the 
enzymatic activity remained intact. The calculated k1 values were 
plotted against the concentrations of each of the compounds (Fig. 2F, H). 
The calculated k2 value for CNZ-3 was 0.66 M− 1 s− 1, while the k2 value 
calculated for CNZ-7 was 0.83 M− 1 s− 1. This indicated that the com-
pound CNZ-7, which has a higher k2 value, inactivates the enzyme 
HsG6PD faster than CNZ-3. This difference in the reactivity between 
these pairs of compounds is because they present different radicals, i.e., 
p-chloro for CNZ-3, while compound CNZ-7 has an n-butyl-ether sub-
stituent in the same position. 
According to the k2 values obtained for the four chemical com-
pounds, JMM-2 and CCM-4 compounds are slower to form the enzyme- 
inhibitor complex than the CNZ-7 and CNZ-3 compounds, which 
showed higher k2 values. For all compounds, we observed that the in-
hibition was concentration-dependent, which indicates that the four 
chemical compounds showed direct inhibition of HsG6PD activity. 
Finally, it is interesting to note that this is the first time that k2 values 
have been reported for G6PD inhibitors. 
Fig. 1. Inactivation of HsG6PD with the compounds JMM-2, CCM-4, CNZ-3, and CNZ-7. The protein concentration of HsG6PD was adjusted to 0.2 mg/mL and 
incubated with increasing concentrations of each of the compounds (0–800 μM) for 2 h at 37 ◦C. The IC50 values for each compound were determined by plotting the 
relative activity of HsG6PD versus compound concentrations (panel A-D). All assays for each compound were performed in triplicate. The bars represent the 
standard error. 
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Fig. 2. Inactivation assay with JMM- 
2, CCM-4, CNZ-3, and CNZ-7 chemi-
cal compounds. The HsG6PD enzyme 
was adjusted to 0.2 mg/mL and 
incubated at 37 ◦C with different 
concentrations of (A) JMM-2 (□ = 0 
μM, ◊ = 300 μM, ο = 400 μM, ∇ =
500 μM, and Δ = 600 μM). (C) CCM-4 
(□ = 0 μM, ◊ = 450 μM, ο = 550 μM, 
∇ = 650 μM, and Δ = 750 μM). (E) 
CNZ-3 (□ = 0 μM, ◊ = 250 μM, ο =
350 μM, ∇ = 450 μM, and Δ = 550 
μM). (D) CNZ-7 (□ = 0 μM, ◊ = 150 
μM, ο = 250 μM, ∇ = 350 μM, and Δ 
= 450 μM). To determine the pseudo- 
first order rate constant values (k1) 
for each compound, the initial veloc-
ity data were fitted using the mono-
exponential decay equation: AR = A0 
e− kt. The second-order rate constant 
values of inactivation (k2) of each of 
the compounds (B) JMM-2, (D) CCM- 
4, (F) CNZ-3, and (H) CNZ-7 were 
obtained by fitting the calculated k1 
value versus the concentration of the 
corresponding compound and adjust-
ing to a linear regression model. All 
experiments were performed in trip-
licate. The bars represent the stan-
dard error.   
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3.1.4. Determination of inhibition type 
To determine the mechanism of action of the four synthetic com-
pounds on the activity of HsG6PD, we created Michaelis–Menten curves 
in the presence of physiological substrates G6P and NADP+ and in the 
presence of increasing inhibitor concentrations (Supplementary Fig. S1). 
The initial activities were fitted to the Michaelis–Menten equation by 
nonlinear regression calculations to obtain the parameters Vmax and Km. 
As seen in Supplementary Fig. S1, when the enzyme HsG6PD was 
incubated with different concentrations of the four inhibitors, the spe-
cific activity (I. U) for both substrates was significantly decreased. 
From the Michaelis–Menten plots of HsG6PD in the presence of 
increased inhibitor concentrations, we determined the type of inhibi-
tion. As seen in Supplementary Fig. S2, compound JMM-2 showed 
noncompetitive-type inhibition of G6P and NADP+ substrates because 
the Vmax values for both substrates decreased (Supplementary Fig. 
S2A–B), while the Km value remained unchanged even at different in-
hibitor concentrations. Compound CCM-4 showed uncompetitive-type 
inhibition for both physiological substrates because the Km and Vmax 
values decreased as the inhibitor concentrations increased (Supple-
mentary Fig. S2C–D). It is important to note that the four compounds 
evaluated in this work showed noncompetitive and uncompetitive in-
hibition and that none of them are competitive-type inhibitors. 
CNZ-3 showed noncompetitive-type inhibition of the G6P substrate 
because the Vmax decreased in the presence of the inhibitor, but the Km 
was not influenced as the inhibitor concentration increased (Supple-
mentary Fig. S2E). However, for the NADP+ substrate, the inhibition 
was of the uncompetitive type because the Vmax and Km decreased with 
all inhibitor concentrations (Supplementary Fig. S2F). Finally, with 
respect to the CNZ-7 inhibitor, we determined uncompetitive-type in-
hibition for both physiological substrates (G6P and NADP+) because the 
values of Vmax and Km decreased in the presence of the four fixed con-
centrations of the inhibitor (Supplementary Fig. S2G–H). 
To determine which of the inhibitors have a greater HsG6PD enzyme 
binding affinity, we calculated the inactivation constants (Ki) for the 
four inhibitors through the fit of the slopes obtained by the double 
reciprocal plot. As shown in Fig. 3, the inhibitor JMM-2 showed a Ki 
calculated for G6P of 142 μM, while that for the NADP+ substrate was 
228 μM (Fig. 3A). The inhibitor CCM-4 showed Ki values of 101 μM and 
42 for G6P and NADP+, respectively (Fig. 3B). In addition, the inhibitors 
CNZ-7 and CNZ-3 showed similar Ki values to the G6P substrate of 223 
μM and 206 μM, respectively, while for the NADP+ substrate, the Ki 
values were 47 μM and 134 μM for the inhibitors CNZ-7 and CNZ-3, 
respectively (Fig. 3C–D). These results are in accordance with the 
mechanism of action determined for the four inhibitors because an 
alteration in G6PD activity was observed in all the compounds when the 
concentrations of the inhibitors were increased. Finally, it is interesting 
to note that the CMM-4 inhibitor showed better HsG6PD enzyme 
binding affinity, while the JMM-2 inhibitor showed less affinity for 
binding with the ES complex for the G6P substrate (142 μM) with respect 
to the NADP+ substrate (228 μM). 
Finally, in Table 2, we show a summary of the biochemical param-
eters determined for the four-hit compounds. As is evident, the CNZ-3 
Fig. 3. Determination of Ki value. The slope values were calculated by fitting Km or Vmax versus the compound concentrations of (A) JMM-2, (D) CCM-4, (B) CNZ-3, 
and (C) CNZ-7. The data represent the mean of three independent experiments. 
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compound showed the best inactivation in the HTS assay and showed 
better second-order inactivation constants (k2), indicating that this 
compound represents the best rate of formation of the enzyme-inhibitor 
complex with the HsG6PD enzyme, but it does not bind at the same site 
as the substrates, and probably CNZ-3 competes near to NADP+ binding 
site as indicated by the inhibition type assay, where we observed that the 
Km value for NADP+ increases, so CNZ-3 presents a higher Ki value 
concerning the other three compounds. 
3.2. Structural studies of the HsG6PD enzyme with inhibitory compounds 
3.2.1. Circular dichroism (CD) and thermal stability assays 
To analyze the effect of inhibitors on the secondary structure of the 
HsG6PD protein, circular dichroism (CD) assays were performed in the 
presence of the IC50 concentration after incubating the enzyme with 
each of the inhibitors. All spectra of HsG6PD with the inhibitors showed 
minimum absorption peaks at 208 nm and 222 nm corresponding to 
β–sheets and α–helices. Nevertheless, as shown in Fig. 4A, when the 
HsG6PD protein was incubated with the inhibitors, differences were 
observed in the minimum absorption signals with respect to the HsG6PD 
enzyme without an inhibitor. The inhibitor that most altered the 
Table 2 
Summary of the constants and types of inhibition obtained from the compounds analyzed in this study.  
Inhibitor Inhibition (%) IC50 (μM) k2 (M− 1 s− 1) Inhibition type Ki (μM) 
G6P NADP+ G6P NADP+
JMM-2 89.5 307 0.50 NC NC 142 228 
CCM-4 47.3 412 0.63 UC UC 101 42 
CNZ-3 92.6 121 0.66 NC UC 223 47 
CNZ-7 68.0 274 0.83 UC UC 206 134 
Without – – – – – 38.5* 6.1* 
NC = noncompetitive inhibition. UC = uncompetitive inhibition. 
* Km without inhibitor. 
Fig. 4. Spectroscopic characterization of recombinant HsG6PD protein in the absence (□) and presence of the four inhibitors (◊) JMM-2, (ο) CCM-4, (∇) CNZ-3, and 
(Δ) CNZ-7 chemical compounds. (A) Far-UV circular dichroism (CD) spectra of HsG6PD. (B) Thermal stability of the HsG6PD protein. (C) Intrinsic fluorescence 
spectra of the HsG6PD enzyme. Inset: Intrinsic fluorescence obtained by subtracting the blank from the values of total fluorescence intensity. The HsG6PD free of 
compounds was fixed as 100%. (D) 8-Anilinonaphthalene-1-sulfonate (ANS) assays of the HsG6PD enzyme. Inset: ANS fluorescence obtained by subtracting the blank 
(ANS without protein; open stars) from the values of total fluorescence intensity. In all the assays, the protein was incubated for 2 h at 37 ◦C prior to measurement. 
The experiments were performed in triplicate. The experimental conditions for all the experiments are described in the Materials and Methods section. 
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secondary structure was JMM-2 because it had a spectrum closer to the 
blank, while the CNZ-3 inhibitor was the second most effective com-
pound in terms of altering the secondary structure of the HsG6PD pro-
tein. Finally, the two inhibitors that altered the secondary structure to a 
lesser extent were the CNZ-7 and CCM-4 inhibitors. These results indi-
cate that all compounds affect the secondary structure of HsG6PD, 
which explains the loss of catalytic activity and is in accordance with 
those observed in biochemical assays, where it was detected that the 
chemical compounds JMM-2 and CNZ-3 showed the best inhibitory 
activity on the HsG6PD protein. 
Because the inhibitors reduce the catalytic activity and alter the 
secondary structure of the HsG6PD protein, it was necessary to evaluate 
the effect on thermal stability (Tm) after incubation with the four in-
hibitors following changes in the CD signal at 222 nm. Important fea-
tures were observed for the enzyme-free inhibitors and in the presence of 
inhibitors, as shown in Fig. 4B. The Tm calculated for the enzyme-free 
inhibitors was 59.6 ◦C, while the inhibitors induced an evident 
decrease (minus 7–16 ◦C) in the Tm values of HsG6PD. The enzyme was 
most affected in the presence of the JMM-2 inhibitor with a decrease of 
16 ◦C in thermal stability (Tm value of 43.4 ◦C), while the CNZ-3 in-
hibitor showed a decrease of 13 ◦C in terms of thermal stability (Tm 
value of 46.5 ◦C) with respect to the inhibitor-free enzyme. In contrast, 
the inhibitors CNZ-7 and CCM-4 showed decreases of 7.8 ◦C and 6.7 ◦C 
(Tm values of 51.8 ◦C and 52.9 ◦C), respectively. These data confirm that 
the four inhibitors have a strong effect on the global stability of the 
HsG6PD protein in addition to their effects on catalysis and loss of 
secondary structure. 
3.2.2. Intrinsic and extrinsic fluorescence assays 
Finally, because of the inhibitors altering the secondary structure 
and the global stability of the HsG6PD protein, we performed intrinsic 
and extrinsic fluorescence assays to determine the changes in the ter-
tiary structure of the protein. The intrinsic fluorescence of the seven 
tryptophan residues contained in the HsG6PD/monomer was monitored 
to determine structural changes in the presence of the four inhibitors. 
We found that the intrinsic fluorescence for the native HsG6PD protein 
without inhibitors showed a peak at 344 nm with a maximum intensity 
of 191 arbitrary units (a.u.) (Fig. 4C), while the presence of the in-
hibitors induced a reduction in the maximum peak of fluorescence: 
12%–51% of the signal was lost in the presence of the inhibitors (Fig. 4C. 
Inset). Compared to the absence of inhibitor, the inhibitor that induced 
the largest changes in the tertiary structure of the protein was JMM-2 
because the maximum intensity of fluorescence decreased by 51% (93 a. 
u.) (Fig. 4C), while the inhibitor CNZ-3 was the second most effective 
inhibitor in terms of inducing alterations in the tertiary structure of the 
protein, where the maximum intensity of fluorescence was reduced by 
40% (115.82 a.u.). Finally, the inhibitors CNZ-7 (151 a.u.) and CCM-4 
(167 a.u.) induced fewer alterations in the tertiary structure of the 
protein, where reductions of 21% and 12%, respectively, were observed 
(Fig. 4C). As previously noted, the decrease in fluorescence intensity 
could be because seven tryptophan residues were exposed to the envi-
ronment after incubation with the inhibitors, inducing the unfolding of 
the native three-dimensional (3D) structure, which caused a negative 
effect on the activity of HsG6PD. Furthermore, these results are again 
related to the grade of inhibition that each molecule shows toward 
HsG6PD as well as the alteration in the secondary structure and the 
global stability of the HsG6PD protein. 
In addition, we used a fluorescent molecular probe (extrinsic fluo-
rescence) as another form to corroborate the alterations in the 3D 
structure of the HsG6PD protein. To identify possible structural changes, 
we monitored the fluorescence of ANS with HsG6PD in the presence of 
the four inhibitors. The ANS molecule has a high affinity for hydro-
phobic regions; therefore, inhibitors that alter the 3D structure of the 
HsG6PD protein to a greater extent will contain more hydrophobic re-
gions and will exhibit higher ANS fluorescence signals. As seen in 
Fig. 4D, all maximum extrinsic fluorescence intensities obtained for 
HsG6PD in the presence of the four inhibitors were higher than those 
obtained for the enzyme without an inhibitor. The HsG6PD enzyme 
without an inhibitor has a maximal fluorescence emission spectrum of 
36 a.u., while compared with the control, HsG6PD incubated with JMM- 
2 produced an ANS spectrum with maximal fluorescence at 486 nm with 
521 a.u. and an increase of 14.8-fold in fluorescence intensity was 
observed. Furthermore, the emission spectrum of the HsG6PD enzyme 
incubated with the inhibitors CNZ-3 and CNZ-4 showed similar 
maximum intrinsic fluorescence intensities of approximately 475 a.u., 
whereas compared to the control, a 13.5-fold increase in fluorescence 
intensity was observed (Fig. 4D. Inset). Finally, compared to HsG6PD 
without an inhibitor, the chemical inhibitor that presented the least 
intensity of extrinsic fluorescence was CCM-4 (418 a.u) with an 11.8- 
fold increase, which indicates that this last compound was the one 
that caused the fewest alterations in the 3D structure of the human G6PD 
protein. Thus, the increase in fluorescence intensity by more than 11.8- 
fold to 14.8-fold in the HsG6PD enzyme in the presence of the inhibitors 
indicated that ANS found more buried hydrophobic pockets in the 
HsG6PD enzyme in the presence of the four inhibitors. 
3.3. Molecular docking 
For the molecular docking study, the most active compounds JMM-2 
and CNZ-3 were selected because they first showed noncompetitive 
inhibition for both substrates and CNZ-3 showed noncompetitive inhi-
bition for G6P and uncompetitive inhibition for NADP+. We performed 
blind molecular docking over the entire protein. To help us understand 
the observed experimental activities, molecular docking studies were 
carried out using Auto Dock Vina software to obtain the plausible 
binding mode of the studied compounds. In addition, this was used to 
deepen our understanding of the interaction between selected hits and 
HsG6PD. In Fig. 5, the in silico study revealed four zones of interaction 
for the JMM-2 compound (Fig. 5A). In general, 70% of the poses ob-
tained in the whole docking experiment had to be repeated in the same 
pocket of HsG6PD that was localized far from the active site and very 
close to the structural NADP+ binding site (zone 3) (Fig. 5A), which is 
involved in the dimerization and stability of the enzyme [35]. The most 
stable protein-ligand complex showed a ΔG = -6.91 ± 0.09 kcal/mol. In 
addition, in zone 3, we observed that phenylpropionic acid showed two 
H-bond interactions with Asn229 and Asn288 and fifteen nonpolar 
contacts. Furthermore, the biphenyl moiety showed π-π interactions 
with Phe221 and Phe373 (Fig. 5B). 
With respect to the docking predicted with CNZ-3, the in silico study 
also revealed four main zones of interaction, as shown in Fig. 5C (Zones 
1–4), and an increase in the formation of hydrogen bridges concerning 
JMM-2 was observed. In zone 1, the protein-ligand interaction showed 
that CNZ-3 bound very close to the active site of HsG6PD and interacted 
with Gln-83 by one H-bond, and nine nonpolar contacts were found 
(Fig. 5D). The most stable protein-ligand complex in zone 1 showed an 
affinity energy of − 5.99 ± 0.03 Kcal/mol. Zone 2 was located near the 
binding of G6P in the active site, and CNZ-3 possesses the ability to form 
one H-bond with Leu433 and nine nonpolar contacts, where the most 
stable protein-ligand complex showed a ΔG = -7.51 ± 0.09 kcal/mol 
(Fig. 5E). With respect to zone 3, we found that CNZ-3 possesses the 
ability to bind a pocket localized very close to the structural NADP+
binding site by a H-bond with Arg487, and eight nonpolar contacts were 
found (ΔG = -6.91 ± 0.02 kcal/mol) (Fig. 5F). It is interesting to note 
that CNZ-3 probably enters the structural NADP+ binding site because 
CNZ-3 interacts with 5 of the 12 amino acids (Arg487, Arg370, Tyr401, 
Lys403, and Tyr503) that participate in the binding of structural 
NADP+. Finally, the zone with the most interactions by hydrogen 
bridges was zone 4 (Fig. 5G), where five H-bonds with Glu244, Lys320, 
Gly321 (2 hydrogen bonds), and Tyr308 were observed. Furthermore, 
we observed eight nonpolar contacts, and the most stable protein-ligand 
complex showed a ΔG = -6.53 ± 0.03 kcal/mol. This pocket was 
localized far from the active site and the structural NADP+ binding site. 
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Fig. 5. Molecular docking of compounds JMM-2 and CNZ-3 on HsG6PD (PDB 2BHL). (A) A general view of the binding affinities of JMM-2 with the HsG6PD protein. 
(B) Zoom of the interaction of zone 3 with JMM-2 on the HsG6PD structure, showing amino acids involved in the binding pocket with the compound. (C) A general 
view of the binding affinities of CNZ-3 with the HsG6PD protein. (D) Zoom of zone 1 with the interactions of CNZ-3 in the HsG6PD structure, showing amino acids 
involved in the binding pocket near the catalytic site NADP+. (E) Zoom of zone 2, showing amino acids of interaction near the catalytic site. (F) Zoom of zone 3, 
showing amino acids involved in the binding pocket near the structural site NADP+. (G) Zoom of zone 4, showing amino acids of interaction with CNZ-3. The 
interactions are shown in black. 
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4. Discussion 
The pentose phosphate pathway (PPP) has been proposed to play a 
crucial role in cancer cells, as it has been associated with increased 
HsG6PD activity [13,22,36]. Because of the important role of HsG6PD 
activity in cancer cells, various mechanisms have been developed to 
inhibit the catalytic activity of this enzyme to decrease the nucleotide 
precursors involved in proliferation, as well as inhibit NADPH, which is 
used for both intracellular ROS detoxification and catabolic metabolism. 
For the above, in this work, we identified four molecules that 
inhibited HsG6PD by more than 40%, named JMM-2, CCM-4, CNZ-3, 
and CNZ-7. The compounds CNZ-3 and CNZ-7 are derivatives of nita-
zoxanide; in another study, it was shown that these compounds have 
trichomonacidal and antileishmanial activity [37]. Then, an orthogonal 
assay was performed to obtain the IC50 values of the four compounds. 
The most effective compound was CNZ-3 (IC50 = 121 μM) (Fig. 6), 
which inactivated the enzyme at lower concentrations than the other 
compounds tested, including 1-dehydroepiandrosterone (DHEA), which 
has been used as an inhibitor of the HsG6PD enzyme, showing an IC50 of 
483 μM [26]. 
The second-order inactivation constant k2 was used to determine the 
ratio formation of the complex enzyme inhibitor with the HsG6PD 
enzyme. Our results showed that CNZ-7 had the best k2, which indicates 
that the inhibitor CNZ-7 bound faster with the HsG6PD enzyme to form 
the enzyme-inhibitor complex and therefore inactivated the enzyme. It 
is important to note that there is no study on G6PD inhibitors in which 
the k2 values of each of the inhibitors have been calculated. 
Kinetic characterization studies revealed that the four compounds 
inhibited the HsG6PD enzyme by noncompetitive and uncompetitive 
type inhibition, while Preuss et al. [26] reported competitive inhibition 
for their four analyzed compounds, including DHEA and 6AN inhibitors 
of the HsG6PD enzyme. In addition, we determined the inactivation 
constants (Ki) for the four inhibitors and observed that all the inhibitors 
have different affinities for binding with HsG6PD. CCM-4 was the in-
hibitor with the best affinity, with a Ki value of 42.6 μM, followed by the 
inhibitor JMM-2, with a Ki value of 142 μM (Fig. 6). 
To demonstrate that the effect of inhibitors not only occurs at the 
functional level but could also occur at the structural level, we evaluated 
the effect of the four inhibitors on the secondary structure of the 
HsG6PD protein by circular dichroism (CD) assay. JMM-2 and CNZ-3 
were the inhibitors that most altered the secondary structure, followed 
by the inhibitors CNZ-7 and CCM-4. These results indicate that all the 
compounds affect the secondary structure of HsG6PD, which explains 
the loss of catalytic activity. In addition, we evaluated the effect of the 
four inhibitors on the thermal unfolding stability (Tm) of the HsG6PD 
protein and found that compared to the enzyme without an inhibitor, 
the enzyme was strongly perturbed at the structural level by all the in-
hibitors. The inhibitors that most perturbed the enzyme were JMM-2 
and CNZ-3, where a decrease of 16 ◦C and 13 ◦C of thermal stability was 
observed. These data confirm that the four inhibitors also have a strong 
effect on the conformational stability of the HsG6PD protein (Fig. 6). 
Additionally, we found that compared to that without the inhibitor, 
the intrinsic fluorescence of the native HsG6PD protein in the presence 
of the four inhibitors induced a reduction in the maximum peak fluo-
rescence intensity from 12% to 51%. These results again suggest that the 
inhibitors affect the native 3D structure of the protein. In addition, the 
fluorescence of the ANS probe was more than 14-fold higher in the 
presence of the inhibitors, indicating that compared to the control 
enzyme, ANS interacted with more exposed hydrophobic sites in the 
HsG6PD enzyme in the presence of the four inhibitors (Fig. 6). It is 
important to mention that this is the first time structural alterations of 
HsG6PD have been studied in the presence of inhibitors. 
Regarding the docking predicted with the compound JMM-2, we 
observed that 70% of the poses were obtained in the pocket far from the 
Fig. 6. Summary of the effects of JMM-2 and CNZ-3 compounds on HsG6PD protein at biochemical and structural levels.  
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active site and close to the structural NADP+ binding site with two H- 
bond interactions. This result is in agreement with the one observed in 
the inhibition assay, where the compound JMM-2 showed 
noncompetitive-type inhibition for G6P and NADP+ substrates, indi-
cating that the compound bound to a place other than the active site, 
meaning that affinity was not affected, but the rate at which the enzyme- 
catalyzed the reaction was affected, which was probably due to a 
conformational change caused by the union of JMM-2 to the enzyme to 
form the inhibitor-enzyme complex (Fig. 6). In addition, JMM-2 was the 
inhibitor that most altered the secondary structure and thermal stability 
and induced the largest changes in the tertiary structure of HsG6PD. 
These results are in concordance with those observed in the molecular 
blind docking analysis, where the stable protein-JMM-2 complex was 
localized close to the structural NADP+ binding site in the HsG6PD 
enzyme, which has been proposed to be crucial for the long-term sta-
bility of the enzyme and stabilization of the dimer state [38]. 
Finally, we observed four interaction zones of HsG6PD in the blind 
molecular docking with compound CNZ-3. Zone 1 was located near the 
active site of the HsG6PD protein and interacts by nonpolar contacts 
with Ala39, Ser40, Gly41, Asp42, and Lys45, which belong to a 
conserved fragment nucleotide-binding fingerprint 38-GxxGGDLA-44 
involved in the binding of NADP+ coenzyme. This result is in concor-
dance with the previously observed inhibition type for the NADP+
substrate, where the inhibition was uncompetitive type, while that in 
zone 2, CNZ-3 was located near the binding site G6P substrate and 
interacted by nonpolar contacts with Lys205 and Glu206, where Lys205 
is the amino acid responsible for substrate binding and catalysis in the 
HsG6PD enzyme. These results could indicate that the binding of CNZ-3 
near the active site is in agreement with the previously observed 
noncompetitive-type inhibition of the G6P substrate because the Vmax 
decreased, but the Km was not influenced (Fig. 6). Regarding zone 3, 
CNZ-3 binds a pocket localized very close to the structural NADP+
binding site, and nonpolar contacts interact with Arg370, Tyr401, 
Lys403 and Tyr503, which are involved in the binding of structural 
NADP+. It is interesting to note that CNZ-3 was the second most effective 
compound in terms of altering the secondary structure, thermal stability 
(loss of 13 ◦C in terms of the Tm value in the absence of the compound) 
and alterations in the tertiary structure of the HsG6PD protein. In 
addition, various working groups have observed that mutations in 
HsG6PD that occur near the structural NADP+ binding site decrease the 
catalytic activity, stability and dimerization of the enzyme 
[3–5,34,38,39]. 
It is interesting to note that all the results shown in this work indicate 
that the HsG6PD protein shows alterations in the activity, secondary 
structure, global stability, and changes in the tertiary structure of the 
protein when the protein was incubated with the inhibitors (Fig. 6). In 
addition, it is important to note that this is the first report in which al-
terations of the secondary and 3D structure of the HsG6PD protein are 
reported in the presence of inhibitors. 
5. Conclusions 
In this study, four new synthetic inhibitors (JMM-2, CCM-4, CNZ-3, 
and CNZ-7) and their effect on HsG6PD activity and structure were 
studied. These new inhibitors showed a higher percentage of inhibition, 
altered the secondary structure and thermal unfolding stability and 
affected the native three-dimensional (3D) structure of the protein. In 
addition, the mechanisms of inhibition were noncompetitive and un-
competitive. This type of inhibition is important in the search for drugs 
since the compounds under study do not compete to bind to the active 
center of the enzyme, which in terms of dose effect, would be equivalent 
to using low doses of the compound to achieve the desired effect. The 
new inhibitors of HsG6PD presented in this work are potential candi-
dates for future in vitro studies in several human antitumor therapies 
since HsG6PD is a key enzyme in the PPP, a pathway that cancer cells in 
proliferating use to cover both the nucleotide precursors needed for 
proliferation and NADPH, a fundamental molecule for the synthesis of 
fatty acids, which are essential in the synthesis of cell membranes. 
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S.T. Méndez, A. Torres-Arroyo, S. Gómez-Manzo, J. Marcial-Quino, M. Ponce- 
Macotela, Y. Rufino-Gonzalez, M. Martínez-Gordillo, G. Palencia-Hernández, 
N. Esturau-Escofet, E. Calderon-Jaimes, J. Oria-Hernández, H. Reyes-Vivas, Novel 
giardicidal compounds bearing proton pump inhibitor scaffold proceeding through 
triosephosphate isomerase inactivation, Sci. Rep. 7 (2017) 7810. 
[33] E.J. Ramírez-Nava, D. Ortega-Cuellar, A. González-Valdez, R.A. Castillo-Rodríguez, 
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